Medical device pioneer Stentys announced that it has established U.S. operations in Princeton, N.J., where the Company will focus its R&D efforts. The Princeton operation will be the cornerstone of the Company's efforts when seeking FDA clearance to market its self-expanding and disconnectable stent platform.

"Establishing U.S. operations is a major milestone for Stentys' future commercial launch," said CEO and co-founder, Gonzague Issenmann. "This is a very exciting time as we are also establishing a radically innovative and improved treatment for acute coronary syndrome (ACS)."

ACS procedures represent half of the $5 billion coronary stenting market. But today's treatment with balloon-expandable stents is plagued by a high incidence of malapposition, a major predictor of stent thrombosis, and that caps the market at a lower value.

"Stentys' platform solves malapposition thanks to its self-expanding feature that ensures optimal apposition in the critical hours and days after the procedure. The stent is constantly applied to the vessel surface during thrombus and vessel spasm relief, as demonstrated in the successful initial clinical experience," explained Issenmann.

Source
Stentys